Novel bradykinin antagonist dimers for the treatment of human lung cancers

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 201-204

  Chan, Daniel ^a   Gera, Lajos ^a   Helfrich, Barbara ^a   Helm, Karen ^a   Stewart, John ^a   Whalley, Eric ^b   Bunn, Paul ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Departments of New Leads Chemistry and Pharmacology   (United States)

Author keywords

bradykinin antagonist; cytotoxic BK dimer; dimer; lung cancer; SCLC

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; CALCIUM; CHOLECYSTOKININ; DELTIBANT; DIMER; ICATIBANT; NEW DRUG;

CALCIUM TRANSPORT; CANCER CELL CULTURE; CELL DEATH; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STABILITY; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PEPTIDE SYNTHESIS; PRIORITY JOURNAL;

EID: 0030175992     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00040-9     Document Type: Conference Paper

References (7)

1. [1] Burch RM, Kyle DJ, Stormann TM. Molecular Biology and Pharmacology of Bradykinin Receptors, Landes Comp, 1993.
2. [2] Gera L, Stewart JM. Immunopharmacology 1996; 33: 174-177.
3. [3] Gera L, Stewart JM, Whalley E, Burkard M, Zuzack JS. Immunopharmacology 1996; 33: 178-182.
4. [4] Bunn P, Chan DC et al. Cancer Res 1992; 52.
5. [5] Becker KL, Gazdar AF. The Endocrine Lung in Health and Disease, Saunders, 1984.
6. [6] Bunn P, Chan DC et al. Cancer Res 1994; 54: 3602-3610.
7. [7] Mitchell FM, Heasley LE et al. J Biol Chem 1995; 270: 8623-8628.